Valuation: PREDILIFE

Market Cap 33.54L 37.62L 31.1L 28.34L 53.36L 36Cr 54.32L 3.74Cr 1.47Cr 19Cr 1.41Cr 1.38Cr 59Cr P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 81.32L 91.21L 75.39L 68.71L 1.29Cr 87Cr 1.32Cr 9.08Cr 3.55Cr 45Cr 3.42Cr 3.35Cr 144.1Cr EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day-5.56%
1 week-6.59%
Current month-15.84%
1 month-16.67%
3 months-52.91%
6 months-72.93%
Current year-71.76%
1 week 0.85
Extreme 0.85
0.9
1 month 0.85
Extreme 0.85
1.02
Current year 0.85
Extreme 0.85
4
1 year 0.85
Extreme 0.85
4
3 years 0.85
Extreme 0.85
24
5 years 0.85
Extreme 0.85
24
10 years 0.85
Extreme 0.85
24
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Director/Board Member 46 01/01/2018
Chairman 56 01/01/2004
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
27/07/23 Buy

Chief Executive Officer

1,200 0.0328%
23/03/22 Sell

Chief Executive Officer

3,000 0.0820%
09/03/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
-5.56%-6.59%-74.01%-85.22% 39.5L
+0.21%-7.67%+61.07%+71.32% 6.89TCr
+1.66%-9.54%+10.39%+60.04% 5.19TCr
+3.14%+4.61%+15.36%+44.42% 4.87TCr
+3.45%+5.01%+32.37%+35.96% 4.31TCr
-2.20%-5.78%+298.44%+532.76% 4.15TCr
+6.43%+2.76%+16.56%+109.23% 4TCr
+1.28%-0.76%+12.67%+45.10% 3.06TCr
-2.21%-14.22%+40.33%-0.94% 2.6TCr
+1.74%-5.30%-12.09%-12.92% 2.23TCr
Average +0.79%-3.62%+40.11%+79.98% 3.73TCr
Weighted average by Cap. +1.58%-3.49%+56.57%+105.30%

Financials

2024 2025
Net sales 5L 6L 5L 4L 8L 5.26Cr 8L 55.04L 21.55L 2.74Cr 20.75L 20.32L 8.74Cr 8L 9L 8L 7L 13.3L 8.91Cr 13.54L 93.28L 36.51L 4.64Cr 35.16L 34.44L 15Cr
Net income -42.65L -47.83L -39.54L -36.04L -67.84L -45Cr -69.06L -4.76Cr -1.86Cr -24Cr -1.79Cr -1.76Cr -76Cr -39.34L -44.13L -36.47L -33.24L -62.59L -42Cr -63.72L -4.39Cr -1.72Cr -22Cr -1.66Cr -1.62Cr -70Cr
Net Debt 35.38L 39.69L 32.8L 29.9L 56.29L 38Cr 57.3L 3.95Cr 1.55Cr 20Cr 1.49Cr 1.46Cr 63Cr 47.78L 53.59L 44.29L 40.37L 76L 51Cr 77.37L 5.33Cr 2.09Cr 27Cr 2.01Cr 1.97Cr 85Cr
Projected Income Statement - Annual - PREDILIFE
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
15/26/15 €0.8500 -5.56% 2
14/26/14 €0.9000 +1.12% 900
13/26/13 €0.8900 0.00% 0
12/26/12 €0.8900 0.00% 165
09/26/09 €0.8900 -2.20% 384

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - PREDILIFE
  1. Stock Market
  2. Stocks
  3. ALPRE Stock